Sort by
Refine Your Search
-
(pro-rata) for 3 years. RMIT funded scholarship provides a stipend of $33,826 per annum (pro-rata) for 3 years. Open now. Open now. 31/12/2023 31/12/2023 One (1). One (1). Standard RMIT PhD enrolment
-
. The PhD project will be multi-disciplinary involving nanofabrication, biophysical characterization, molecular immunology, virology, and sensor applications. This project will build on the ability
-
key skills in synthesis and characterisation of nanomaterials, nano–bio interactions and immunology. The PhD will further participate in established collaborations with other leading nanotechnology
-
and functional T cell assays. The PhD candidate: The preferred PhD candidate will have completed an Honours or Masters degree in immunology, microbiology, bioinformatics, biostatistics or a related
-
immunological techniques, e.g. ELISA, ELISPOT, immunohistology, proliferation and functional immune-cell assays. The PhD candidate: The preferred PhD candidate will have done an Honours or Masters in immunology
-
characterisation of nanomaterials, nano-bio interactions and immunology. The PhD candidate will further participate in established collaborations with other leading nanotechnology laboratories across multiple
-
Scholarship will fund a 3-year PhD candidature to work in the Cancer, Ageing & Vaccine Laboratory (SHBS). Project is a collaboration with WEHI and Hudson Institute to improve cancer diagnosis
-
, ELISPOT, immunohistology, proliferation and functional T cell assays. The PhD candidate: The preferred PhD candidate will have done an Honours or Masters in either immunology, psychology, bioinformatics
-
PhD candidate: The preferred PhD candidate will have done an Honours or Masters in either immunology, or vaccines, microbiology, bioinformatics, biostatistics or a related discipline. References: [1
-
unique ovarian cancer animal model and blood samples from multiple human clinical trials. The PhD candidate: The preferred PhD candidate will have done an Honours or Masters in either immunology, oncology